Abstract: The present invention provides a new stable pharmaceutical composition of granulocyte-colony stimulating factor (G-CSF).

Abstract: The invention relates to a modifying agent comprising a water soluble polymer, wherein the water soluble polymer comprises at least one reactive selenium group, said reactive selenium group being capable of reacting with a thiol group thereby forming an —Se—S— bond. Furthermore, the invention relates to a method for producing said modifying agents and their use in the modification of pharmaceutically active agents, e.g. G-CSF. Additionally, the invention concerns conjugates comprising a water-soluble polymer and a pharmaceutically active agent, wherein the water-soluble polymer is linked via a S—Se-bond to agent and a method for their production and their use as medicaments. Finally, the invention concerns a pharmaceutical composition comprising the inventive conjugates.

Abstract: The present invention relates to the pharmaceutical composition comprising a non-detergent sulphobetaine (NDSB).

Abstract: The invention relates to the synthetic gene coding for hG-CSF which enables expression in E. coli with an improved expression level of the recombinant hG-CSF regarding the total cellular proteins after expression.

Abstract: The present invention provides a new stable pharmaceutical composition of granulocyte-colony stimulating factor (G-CSF).

Abstract: The present invention provides a new stable pharmaceutical composition of granulocyte-colony stimulating factor (G-CSF).

Abstract: The invention relates to the process for the isolation and/or purification of biologically active proteins, preferably TNF-alpha or TNF-alpha analogues. The process of the present invention results in the production of high yields of proteins, preferably TNF-alpha or TNF alpha analogues with a purity of greater than 98%. The described process is particularly suitable for the industrial production of proteins, preferably TNF-alpha or TNF-alpha analogues.

Abstract: The present invention relates to the pharmaceutical composition comprising a non-detergent sulphobetaine (NDSB).

Abstract: The present invention provides a new stable pharmaceutical composition of granulocyte-colony stimulating factor (G-CSF).

Abstract: The invention relates to the synthetic gene coding for hG-CSF which enables expression in E. coli with an improved expression level of the recombinant hG-CSF regarding the total cellular proteins after expression.

Abstract: The invention relates to a new process for the production of a biologically active heterologous protein. The process involves the performance of biosynthesis by adjusting conditions in such a way that the process enables the accumulation of correctly folded precursor of the heterologous protein already in inclusion bodies. The invention further comprises washing and solubilising of the inclusion bodies, especially under non-denaturating conditions.

Abstract: The invention relates to the process for the isolation of biologically active granulocyte colony stimulating factor (G-CSF), which enables the separation of correctly folded biologically active monomeric molecules of G-CSF from the incorrectly folded, biologically inactive monomeric, oligo- or polymeric and also from aggregated molecules of G-CSF by using immobilized metal affinity chromatography. The process of the invention, if desired the whole process, can be advantageously performed under native conditions. The biologically active G-CSF with a purity of greater than 95% is thus obtained. Only two additional chromatographic steps, cationic exchange chromatography and gel filtration, are then preferably applied to remove the traces of impurities. The entire process results in the production of higher yields of G-CSF with a purity of greater than 99%. The described process is particularly suitable for the industrial production of G-CSF.